WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 31-July-2017 (data as of 19-July-2017)
Next overall update Fall-2017
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 36'6801 Infant (under 12 months) mortality rate: 22
GDP / capita (US$): 37'3221 Child (under 5 years) mortality rate: 32

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 127'749  127'975  128'163  128'313  128'426  127'534  124'516  117'827 
Births 1'043  1'053  1'063  1'073  1'082  1'166  1'288  1'630 
Surviving infants 1'041  1'051  1'061  1'070  1'079  1'162  1'283  1'619 
Pop. less than 5 years 5'343  5'396  5'445  5'496  5'540  5'955  6'781  8'618 
Pop. less than 15 years 16'525  16'626  16'744  16'870  16'994  18'853  23'004  27'788 
Female 15-49 years 26'076  26'316  26'567  26'788  26'984  29'438  31'539  30'706 

Number of reported cases

(Click for retrospective incidence data for Japan)
Diphtheria
ChartChart
  66 
Japanese encephalitis
ChartChart
  11 
Measles
ChartChart ChartChart
  165  35  462  229  228  22'497  3'259  13'219 
Mumps
ChartChart
  159'031  81'046  46'340  40'999  71'549  132'659 
Pertussis
ChartChart
  3'011  2'675  2'066  1'663  4'087  3'787  583  5'033 
Polio*
ChartChart
 
Rubella
ChartChart
  126  163  320  14'359  2'353  3'120 
Rubella (CRS)
ChartChart
  31 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  129  120  126  127  116  90  47  50 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Japan)
Vaccine year result method % card seen                                                
BCG          98  84  93  93  95  96  85 
DTP1          99  99*  99*  99*  99*  99* 
DTP3          99  96  99*  99*  99*  85  87  60 
DTP4          85  91  99* 
IPV1          99  99* 
HepB_BD         
HepB3         
Hib3          99*  99* 
JapEnc          99*  99*  99*  99*  99* 
MCV1          96  96  98  95  96  96  66  69 
MCV2          93  93  94  93  92 
MenA         
PCV1          99*  99* 
PCV2          99*  99* 
PCV3          99*  99* 
Pol3          99  99*  99*  99  99  99  90 
Rota1         
RotaC         
RCV1          96  96  98  95  96 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Japan)
BCG
ChartChart
  84  84  93  93  95  85 
DTP1
ChartChart
  99  98  98  98  99  88  96  82 
DTP3
ChartChart
  99  96  96  96  97  85  90  60 
HepB3
 
HepB_BD
 
Hib3
ChartChart
  99  96 
MCV1
ChartChart
  96  96  98  95  96  96  73  69 
MCV2
ChartChart
  93  93  94  93  92 
PCV3
ChartChart
  99  96 
Pol3
ChartChart
  99  99  99  99  99  98  90 
RCV1
ChartChart
  96  96  98  95  96  96  73 
RotaC
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 1'741  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 1 year; Yes
DT 11 years; Yes
DTaPIPV 3, 4.5, 6, 18 months; Yes
HIB 2, 3, 4 months; 1 year; Yes
HPV 13 years (x3); Yes
Influenza_Adult >= 65 years; Yes and adults with chronic illness
JE_Inactd 36, 37 months; 4, 9 years; Yes
MR 1, 5 years; Yes
Pneumo_conj 2, 3, 4 months; 1 year; Yes
Pneumo_ps 65 years; Yes
Varicella 12, 18 months; Yes

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  No  No  No  No  No 
What years does the MYP cover? number 5y  5y           
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number 1'741  1'741  1'741  1'748  1'742  1'725  1'724 
Nº districts with measles (MCV1) coverage >=95% number NA  NA  NA         
% of districts with MCV1 coverage >=95% From 0 to 100%              

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% NA  NA  NA         

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.